تسلسل الإكسوم الكامل - ثلاثي

This full exome sequencing test aims to identify gene sets for diagnosing rare genetic disorders by evaluating nearly all protein-coding genes in the human genome in one test. It includes routine reanalysis and covers costs for up to two years.

• The description claims that the test may discover incidental genetic changes of medical importance but not directly related to the primary reason for exome sequencing.
• The description claims that Enigma Genomics will report any incidental results related to adult neurodegenerative diseases without available interventions.
• The description claims that incidental results are considered part of Enigma Genomics' duty to inform policy, and withdrawal is not an option even if the result falls under secondary ACMG results.